Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This investigational combination therapy consists of triamcinolone (a corticosteroid), hyaluronic acid (a viscosupplement), and dextrose (a hypertonic sugar solution), administered via ultrasound-guided intra-articular injection. Developed by researchers at Taipei Medical University, the regimen is designed to treat knee osteoarthritis by simultaneously addressing joint inflammation, restoring synovial fluid viscosity, and stimulating connective tissue repair through prolotherapy. Triamcinolone acts as a glucocorticoid receptor agonist to reduce inflammation, hyaluronic acid provides mechanical lubrication and shock absorption, and dextrose acts as an irritant to trigger a localized healing response in the joint's connective tissues.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on triamcinolone + hyaluronic acid + dextrose.